AR105875A1 - Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio - Google Patents
Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominioInfo
- Publication number
- AR105875A1 AR105875A1 ARP160102662A ARP160102662A AR105875A1 AR 105875 A1 AR105875 A1 AR 105875A1 AR P160102662 A ARP160102662 A AR P160102662A AR P160102662 A ARP160102662 A AR P160102662A AR 105875 A1 AR105875 A1 AR 105875A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- nr11r12
- halo
- groups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) y sales de los mismos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia. Reivindicación 1: Un compuesto de formula (1) o una sal del mismo en la que: R¹ es -alquilo C₁₋₃ o ciclopropilo; R² es H o -alquil C₀₋₃-cicloalquilo C₃₋₇, donde el grupo cicloalquilo no está sustituido o está sustituido con uno, dos o tres grupos R⁵ que pueden ser iguales o distintos; R³ es -H, -alquilo C₁₋₄, ciclopropilo o -(CH₂)ₚOR¹⁰; R⁴ es a) fenilo (que puede estar no sustituido o sustituido con uno, dos o tres grupos R⁷ que pueden ser iguales o distintos); b) un grupo heteroarilo de 5 ó 6 miembros (que puede estar no sustituido o sustituido con -alquilo C₁₋₃, -O-alquilo C₁₋₃, o halo); c) un grupo heteroarilo de 9 a 11 miembros (que puede estar no sustituido o sustituido con uno, dos o tres grupos, que pueden ser iguales o distintos, seleccionados de -alquil C₁₋₃-R⁸, -OCH₃, -O-alquil C₂₋₃-R⁸, halo, oxo, -O-CF₃ y -CN); o d) -(CH₂)ₙ-fenilo; p es 1 ó 2; n es 1 ó 2; R⁵ es halo, fenilo, -alquil C₁₋₆-R⁸, -CO₂H, -OCH₃, -O-alquil C₂₋₆-R⁸, -CN, -OH o -NHR⁶; R⁶ es -H, -C(O)OC(CH₃)₃, -alquilo C₁₋₆, -cicloalquilo C₃₋₇, un grupo heterociclilo de 4 a 7 miembros, o -alquil C₂₋₃-O-alquilo C₁₋₃ donde los grupos -alquilo C₁₋₆ y -cicloalquilo C₃₋₇ pueden estar opcionalmente sustituidos con uno, dos o tres fluoro; R⁷ es -NR¹¹R¹², -alquilo C₁₋₃, halo, -CO₂R¹⁰, -CH₂OH, -CH(R¹¹)OR¹⁰, -C(O)alquilo C₁₋₃, -CH(R¹⁰)NR¹¹R¹², -CN, -CHF₂, -CF₃, -OH, -OCHF₂, -OCF₃, -OCH₃, -O-alquil C₂₋₆-R⁹, -alquil C₁₋₆-R⁹ o -O-piperidinilo; R⁸ es -H, -OR¹⁰, -CO₂C(CH₃)₃ o -NR¹¹R¹²; R⁹ es -H, -OR¹⁰ o -NR¹¹R¹²; R¹⁰ es -H o -alquilo C₁₋₃; R¹¹ y R¹² están cada uno seleccionado independientemente de -H, -alquilo C₁₋₃ y -alquil C₁₋₃NR¹³R¹⁴; o R¹¹ y R¹² pueden unirse junto con el nitrógeno al que están unidos para formar un grupo heterociclilo de 4 a 7 miembros, opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente de -alquilo C₁₋₃, -OH y F; y R¹³ y R¹⁴ están cada uno seleccionado independientemente de -H, -alquilo C₁₋₃ y -C(O)CH₃.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562213137P | 2015-09-02 | 2015-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105875A1 true AR105875A1 (es) | 2017-11-15 |
Family
ID=56943472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102662A AR105875A1 (es) | 2015-09-02 | 2016-08-31 | Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10428026B2 (es) |
| EP (1) | EP3344615A1 (es) |
| JP (1) | JP6532599B2 (es) |
| KR (1) | KR102088157B1 (es) |
| CN (1) | CN108137542B (es) |
| AR (1) | AR105875A1 (es) |
| AU (1) | AU2016315360B2 (es) |
| CA (1) | CA2996245C (es) |
| CL (1) | CL2018000565A1 (es) |
| CO (1) | CO2018002211A2 (es) |
| CR (1) | CR20180138A (es) |
| DO (1) | DOP2018000062A (es) |
| EA (1) | EA033679B1 (es) |
| HK (1) | HK1249504A1 (es) |
| IL (1) | IL257431B (es) |
| MA (1) | MA43940A (es) |
| MX (1) | MX2018002699A (es) |
| PE (1) | PE20181273A1 (es) |
| PH (1) | PH12018500446A1 (es) |
| TW (1) | TWI724022B (es) |
| UY (1) | UY36875A (es) |
| WO (1) | WO2017037116A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA43940A (fr) * | 2015-09-02 | 2018-12-12 | Glaxosmithkline Ip No 2 Ltd | Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine |
| AU2016326864A1 (en) | 2015-09-22 | 2018-03-22 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
| BR112018006545A2 (pt) | 2015-10-05 | 2018-10-16 | Glaxosmithkline Ip No 2 Ltd | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? |
| JP6954921B2 (ja) | 2016-04-07 | 2021-10-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としてのピリジル誘導体 |
| RU2018142988A (ru) * | 2016-05-24 | 2020-06-25 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена |
| JOP20190192A1 (ar) | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| GB201703282D0 (en) | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
| CN108003085A (zh) * | 2017-12-19 | 2018-05-08 | 张开良 | 一种药物中间体芳甲酰基吲哚衍生物的合成方法 |
| CN108484494B (zh) * | 2018-06-15 | 2021-07-30 | 沈阳药科大学 | 2-氧代-1,2-二氢吡啶-4-甲酸类化合物 |
| GB201814167D0 (en) | 2018-08-31 | 2018-10-17 | Glaxosmithkline Ip No 2 Ltd | Compounds |
| BR112022026364A2 (pt) | 2020-06-23 | 2023-01-17 | Genentech Inc | Composto macrocíclico, compostos, complexo, uso de um composto, composição farmacêutica, métodos para tratar câncer e para tratar uma condição fibrótica e invenção |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1357111E (pt) | 2000-12-28 | 2009-10-20 | Shionogi & Co | Derivados de 2-piridona com afinidade para receptores de canabinóides do tipo 2 |
| DE60329981D1 (de) | 2002-02-19 | 2009-12-24 | Shionogi & Co | Antipruriginosa |
| US7629347B2 (en) | 2002-10-09 | 2009-12-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
| ES2345146T3 (es) | 2002-11-18 | 2010-09-16 | Schering Corporation | Inhibidores de 17beta-hidroxiesteroides deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| EP1433788A1 (en) | 2002-12-23 | 2004-06-30 | Aventis Pharma Deutschland GmbH | Pyrazole-derivatives as factor Xa inhibitors |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| TW200700392A (en) | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| JP5758630B2 (ja) * | 2007-11-15 | 2015-08-05 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Ｐａｒｐ阻害剤としてのピリダジノン誘導体 |
| EP2306828A4 (en) * | 2008-06-25 | 2011-06-29 | Glaxosmithkline Llc | INHIBITORS OF PROLYL HYDROXYLASES |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| BR112014031068A2 (pt) * | 2012-06-12 | 2017-06-27 | Abbvie Inc | derivados piridinona e piridazinona |
| JP6204484B2 (ja) | 2012-11-08 | 2017-09-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用なヘテロアリール置換ピリジル化合物 |
| WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| KR20160038008A (ko) | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
| DE102013215912B3 (de) * | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| MX2016007346A (es) * | 2013-12-09 | 2016-09-13 | Abbvie Inc | Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio. |
| AR105646A1 (es) | 2015-08-11 | 2017-10-25 | Actelion Pharmaceuticals Ltd | Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida |
| MA43940A (fr) | 2015-09-02 | 2018-12-12 | Glaxosmithkline Ip No 2 Ltd | Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine |
| BR112018006545A2 (pt) | 2015-10-05 | 2018-10-16 | Glaxosmithkline Ip No 2 Ltd | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? |
| JP6954921B2 (ja) | 2016-04-07 | 2021-10-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ブロモドメイン阻害薬としてのピリジル誘導体 |
| RU2018142988A (ru) | 2016-05-24 | 2020-06-25 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Производные пиридиндикарбоксамида в качестве ингибиторов бромодомена |
-
2016
- 2016-08-31 MA MA043940A patent/MA43940A/fr unknown
- 2016-08-31 JP JP2018511236A patent/JP6532599B2/ja active Active
- 2016-08-31 PE PE2018000339A patent/PE20181273A1/es unknown
- 2016-08-31 MX MX2018002699A patent/MX2018002699A/es unknown
- 2016-08-31 EA EA201890331A patent/EA033679B1/ru not_active IP Right Cessation
- 2016-08-31 CN CN201680059250.XA patent/CN108137542B/zh active Active
- 2016-08-31 UY UY0001036875A patent/UY36875A/es not_active Application Discontinuation
- 2016-08-31 EP EP16766865.6A patent/EP3344615A1/en active Pending
- 2016-08-31 TW TW105128127A patent/TWI724022B/zh not_active IP Right Cessation
- 2016-08-31 US US15/757,199 patent/US10428026B2/en active Active
- 2016-08-31 WO PCT/EP2016/070519 patent/WO2017037116A1/en active Application Filing
- 2016-08-31 KR KR1020187009349A patent/KR102088157B1/ko active IP Right Grant
- 2016-08-31 CA CA2996245A patent/CA2996245C/en active Active
- 2016-08-31 CR CR20180138A patent/CR20180138A/es unknown
- 2016-08-31 AU AU2016315360A patent/AU2016315360B2/en not_active Ceased
- 2016-08-31 AR ARP160102662A patent/AR105875A1/es unknown
-
2018
- 2018-02-08 IL IL257431A patent/IL257431B/en active IP Right Grant
- 2018-02-27 CO CONC2018/0002211A patent/CO2018002211A2/es unknown
- 2018-03-01 PH PH12018500446A patent/PH12018500446A1/en unknown
- 2018-03-02 DO DO2018000062A patent/DOP2018000062A/es unknown
- 2018-03-02 CL CL2018000565A patent/CL2018000565A1/es unknown
- 2018-07-11 HK HK18108983.2A patent/HK1249504A1/zh unknown
-
2019
- 2019-08-08 US US16/535,139 patent/US10927080B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2018000062A (es) | 2018-03-30 |
| KR102088157B1 (ko) | 2020-03-12 |
| IL257431A (en) | 2018-04-30 |
| CN108137542B (zh) | 2023-10-27 |
| CR20180138A (es) | 2018-07-16 |
| US20180258044A1 (en) | 2018-09-13 |
| EA033679B1 (ru) | 2019-11-15 |
| TWI724022B (zh) | 2021-04-11 |
| EA201890331A1 (ru) | 2018-08-31 |
| US10428026B2 (en) | 2019-10-01 |
| KR20180043366A (ko) | 2018-04-27 |
| US20190359572A1 (en) | 2019-11-28 |
| AU2016315360B2 (en) | 2019-09-12 |
| BR112018003827A2 (pt) | 2018-09-25 |
| EP3344615A1 (en) | 2018-07-11 |
| JP6532599B2 (ja) | 2019-06-19 |
| WO2017037116A1 (en) | 2017-03-09 |
| HK1249504A1 (zh) | 2018-11-02 |
| CO2018002211A2 (es) | 2018-05-21 |
| UY36875A (es) | 2017-03-31 |
| CL2018000565A1 (es) | 2018-07-06 |
| CN108137542A (zh) | 2018-06-08 |
| MX2018002699A (es) | 2018-04-13 |
| PE20181273A1 (es) | 2018-08-03 |
| US10927080B2 (en) | 2021-02-23 |
| AU2016315360A1 (en) | 2018-03-22 |
| JP2018526383A (ja) | 2018-09-13 |
| CA2996245C (en) | 2023-10-17 |
| CA2996245A1 (en) | 2017-03-09 |
| IL257431B (en) | 2021-04-29 |
| PH12018500446A1 (en) | 2018-09-10 |
| MA43940A (fr) | 2018-12-12 |
| TW201718504A (zh) | 2017-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105875A1 (es) | Derivados de 2-oxo-1,2-dihidropiridina como inhibidores de bromodominio | |
| AR110922A1 (es) | Compuestos inhibidores del vih | |
| AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| AR111419A1 (es) | Compuestos fusionados de indazol piridona como antivirales | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
| AR099788A1 (es) | Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| AR098776A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR109487A1 (es) | Derivados de imidazo-2-il-piridin-2-ona como inhibidores de la unión de las proteínas bet | |
| AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas | |
| AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt | |
| AR102972A1 (es) | Compuestos de dihidropirimidin-2-ona y su uso médico | |
| AR093035A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |